Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma
NCT03679754Phase 1Completed
- Sponsor
- Alaunos Therapeutics
- Start
- Sep 2018
- Primary completion
- Apr 2019
- Modality
- Gene Editing, Gene Silencing, Adenoviral Vectors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ad-rts-hil-12 in glioblastoma (GBM), sponsored by Alaunos Therapeutics. Primary endpoints: Safety of Intratumoral Ad-RTS-hIL-12 and Oral Veledimex up to 5 months and Tolerability of Intratumoral Ad-RTS-hIL-12 and Oral Veledimex up to 4 months. Started Sep 2018; status: completed.
02
Drugs
ad-rts-hil-12
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03679754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03679754.